Sonepiprazole

Sonepiprazole

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Uncontrolled
Identifiers
IUPAC name 4-(4-{2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl}piperazin-1-yl)benzenesulfonamide
CAS Number	170858-34-1
PubChem CID	133079
IUPHAR/BPS	980
ChemSpider	117441
UNII	O609V24217
Chemical and physical data
Formula	C21H27N3O3S
Molar mass	401.52 g/mol
3D model (Jmol)	Interactive image
SMILES O=S(=O)(N)c1ccc(cc1)N2CCN(CC2)CC[C@@H]4OCCc3ccccc34

Sonepiprazole (U-101,387, PNU-101,387-G) is a drug of the phenylpiperazine class which acts as a highly selective D₄ receptor antagonist. In animals, unlike D₂ receptor antagonists like haloperidol, sonepiprazole does not block the behavioral effects of amphetamine or apomorphine, does not alter spontaneous locomotor activity on its own, and lacks extrapyramidal and neuroendocrine effects. However, it does reverse the prepulse inhibition deficits induced by apomorphine, and has also been shown to enhance cortical activity and inhibit stress-induced cognitive impairment. As a result, it was investigated as an antipsychotic for the treatment of schizophrenia in a placebo-controlled clinical trial, but in contrast to its comparator olanzapine no benefits were found and it was not researched further for this indication.